報價延遲最少15分鐘:2025/07/20 13:08 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.54 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.55/-2.05
|
|
企業價值
1.45B
|
| 資產負債 |
|
每股賬面淨值
4.08
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 13:08 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia. |
